Cepheid
This article was originally published in The Gray Sheet
Executive Summary
Maker of microfluidic systems for detection and analysis of nucleic acids raises $34.5 mil. in its initial public offering, the company announces July 13 (1"The Gray Sheet" July 3, p. 11). With exercise of 750,000 over-allotment shares by underwriters UBS Warburg, Prudential Vector Healthcare and Invemed Associates, the IPO included a total of 5.75 mil. shares at $6 each. Proceeds will be used for R&D and expansion of manufacturing. Cepheid shares trade on the Nasdaq exchange under the symbol "CPHD"
You may also be interested in...
Cepheid
Initial public offering of 5 mil. shares at $6 each June 21 represents a reduction in the originally proposed price range of $10-12 per share (1"The Gray Sheet" May 1, p. 19). The Sunnyvale, California maker of microfluidic systems for detection and analysis of nucleic acids plans to use the proceeds from the $30 mil. offering for R&D, expansion of manufacturing and other general corporate purposes. Cepheid shares trade on the Nasdaq market under the symbol "CPHD." Underwriters UBS Warburg, Prudential Vector Healthcare and Invemed Associates hold an overallotment option for 750,000 additional shares
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.